Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Christina Bahrs, Miriam Kesselmeier, Martin Kolditz, Santiago Ewig, Gernot Rohde, Grit Barten-Neiner, Jan Rupp, Martin Witzenrath, Tobias Welte, Mathias W. Pletz. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021

Member's Comments

No comment yet.

Related content which might interest you: Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Characteristics of patients with serotype 5 pneumococcal pneumonia Source: Virtual Congress 2020 – Clinical challenges in pneumonia Year: 2020 Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia Source: Eur Respir J 2010; 36: 1073-1079 Year: 2010 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 Influenza and pneumococcal vaccination in patients with COPD Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden Source: Eur Respir J 2016; 47: 1208-1218 Year: 2016 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Clinical effectiveness of pneumococcal vaccination against nonbacteremic pneumonia in people over 50 years Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010